Calcium 2-aminoethylphosphate

Calcium 2-aminoethylphosphate (Ca-AEP or Ca-2AEP) is a compound discovered by the biochemist Erwin Chargaff in 1941. It is the calcium salt of phosphorylethanolamine. It was patented by Hans Alfred Nieper and Franz Kohler.

Calcium 2-aminoethylphosphate

Names
Preferred IUPAC name Calcium 2-aminoethyl phosphate
Identifiers
CAS Number	10389-08-9 N
3D model (JSmol)	Interactive image
ChemSpider	14508512 Y
PubChem CID	19985431
UNII	Y68G4M097Y N
CompTox Dashboard (EPA)	DTXSID40601671
InChI InChI=1S/C2H8NO4P.Ca/c3-1-2-7-8(4,5)6;/h1-3H2,(H2,4,5,6);/q;+2/p-2 Y Key: SYLKQIHLJRQWAY-UHFFFAOYSA-L Y
SMILES C(COP(=O)([O-])[O-])N.[Ca+2]
Properties
Chemical formula	C2H6CaNO4P
Molar mass	179.13 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is YN ?) Infobox references

Terminology and glossary

Calcium 2-amino ethyl phosphoric acid (Ca-AEP or Ca-2AEP) is also called calcium ethylamino-phosphate (calcium EAP), calcium colamine phosphate, calcium 2-aminoethyl ester of phosphoric acid, and calcium 2-amino ethanol phosphate

2-AEP plays a role as a component in the cell membrane and at the same time has the property to form complexes with minerals. This mineral transporter goes into the outer layer of the outer cell membrane where it releases its associated mineral and is itself metabolized with the structure of the cell membrane.

History, treatments, uses, and risks

Ca-AEP was discovered by Erwin Chargaff in 1953.

According to the U.S. National Multiple Sclerosis Society Calcium EAP is often promoted as a cure or therapy for Multiple Sclerosis and many other diseases. However, it states that it is not recommended by its medical advisory board, and also notes that the Food and Drug Administration has classified it as unsafe and unapproved for use.

Calcium 2-AEP is manufactured by numerous nutraceutical companies and is sold online and in health food stores.